Letrozole Accord (Letrozole)

Letrozole blocks the aromatase enzyme, which is responsible for converting adrenal androgens into estrogen in peripheral tissues. By inhibiting this conversion, systemic estrogen levels drop, depriving estrogen‑dependent cancer cells of a key growth signal and thereby slowing tumor progression.

The prescribed dose of Letrozole Accord is determined by the treating physician based on the patient’s clinical condition, disease stage, and individual health factors. Dosage decisions are made by qualified healthcare professionals and should not be altered without medical guidance.

Letrozole is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy due to known teratogenic risk. It is also not recommended during breastfeeding because it may pass into breast milk and affect the infant. Women of childbearing potential should use effective contraception.

To request Letrozole Accord, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Letrozole, as a third‑generation aromatase inhibitor, generally provides more potent estrogen suppression than earlier agents like anastrozole. Compared with selective estrogen receptor modulators such as tamoxifen, letrozole does not act on the receptor itself but reduces estrogen production, which can be advantageous in postmenopausal patients but requires monitoring of bone health.

Letrozole Accord tablets should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture, heat, and direct sunlight to maintain stability and potency throughout its shelf life.

Letrozole Accord is taken orally, usually as a whole tablet swallowed with water. It is typically taken once daily, at the same time each day, unless the prescribing physician advises a different schedule based on the patient’s treatment plan.

Serious risks include severe liver injury, osteoporotic fractures, deep vein thrombosis or pulmonary embolism, myocardial infarction, and rare but potentially life‑threatening allergic reactions. Patients should be monitored regularly for signs of these events, and any concerning symptoms should be reported to a healthcare professional promptly.

Letrozole Accord should not be used by pregnant or breastfeeding women, premenopausal patients without ovarian suppression, individuals with known hypersensitivity to letrozole or any component of the formulation, and patients with severe liver impairment. Contraindications and precautions must be evaluated by the prescribing clinician.